Which Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI?

Sara Appino, The Motley Fool

Mon, August 3, 2026 astatine 6:45 AM CDT 5 min read

While State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) offers wide vulnerability to established healthcare giants astatine a minimal cost, State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides a much volatile, equal-weighted absorption connected the biotechnology sub-sector.

Choosing betwixt these 2 funds depends connected the desired level of manufacture attraction and volatility tolerance. The State Street Health Care Select Sector SPDR ETF provides a diversified introduction into the healthcare giants of the S&P 500, whereas the smaller State Street SPDR S&P Biotech ETF leans heavy into the high-risk imaginable of research-focused firms. This examination analyzes cost, performance, and hazard profiles to spot which attack fits your portfolio.

Snapshot (cost & size)

Beta measures terms volatility comparative to the S&P 500; beta is calculated from monthly returns implicit the disposable money past (up to 5 years). The 1-yr instrumentality represents full instrumentality implicit the trailing 12 months. Dividend output is the trailing-12-month organisation yield.

The State Street Health Care Select Sector SPDR ETF is notably much affordable, with an disbursal ratio of 0.08% compared to the 0.35% charged by the biotech fund. This outgo quality is accompanied by a 1.18 percent constituent output vantage for XLV, appealing to those seeking higher currency distributions.

Performance & hazard examination

What's wrong

The State Street Health Care Select Sector SPDR ETF tracks 60 large-cap stocks wrong the Health Care Select Sector Index, offering vulnerability to pharmaceuticals, aesculapian equipment, and healthcare providers. Because it is market-cap weighted, its largest positions see Eli Lilly (NYSE:LLY) astatine 15.97%, Johnson + Johnson (NYSE:JNJ) astatine 10.67%, and Abbvie (NYSE:ABBV) astatine 7.76%. The portfolio reflects 99% healthcare vulnerability with nominal currency holdings. It was launched successful 1998. State Street Health Care Select Sector SPDR ETF has paid $2.53 per stock implicit the trailing 12 months, which connected its caller ~$163.52 stock terms works retired to a 1.6% yield.

The State Street SPDR S&P Biotech ETF follows a modified equal-weight strategy crossed 155 biotechnology stocks, reducing the power of idiosyncratic giants successful favour of broader manufacture participation. Its largest positions see Apogee Therapeutics (NASDAQ:APGE) astatine 1.64%, Oruka Therapeutics (NASDAQ:ORKA) astatine 1.39%, and Dianthus Therapeutics (NASDAQ:DNTH) astatine 1.37%. This attraction results successful 100% healthcare vulnerability with a absorption connected high-growth sub-sectors. It was launched successful 2006. State Street SPDR S&P Biotech ETF has paid $0.57 per stock implicit the trailing 12 months, which connected its caller ~$151.46 stock terms works retired to a 0.4% yield.